Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose-Finding, Phase 1/2a Study to Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II

NCT07131722 is registered in ClinicalTrials.gov with PRG Science & Technology Co., Ltd. as lead sponsor.

NCT NCT07131722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07131722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose-Finding, Phase 1/2a Study to Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II
Lead sponsor
PRG Science & Technology Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
July 31, 2028
Enrollment
25 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neurofibromatosis type ii, nf2